Research graph
References from Large-scale randomized double-blind field clinical trial for safety and efficacy assessment of the DNA vaccine Neoleish against canine leishmaniasis. Local targets link to admitted publications; unresolved targets remain external evidence.
Canine Leishmaniasis: An Overview of the Current Status and Strategies for Control
10.1155/2018/3296893 · 2018 · External reference
Guidelines for prevention of leishmaniasis in dogs
10.2460/javma.236.11.1200 · 2010 · External reference
Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis
10.1007/s00430-014-0367-9 · 2015 · External reference
Intramuscular Immunization with a Liposomal Multi-Epitope Chimeric Protein Induces Strong Cellular Immune Responses against Visceral Leishmaniasis
10.3390/vaccines11081384 · 2023 · External reference
A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice
10.1016/j.vaccine.2021.04.004 · 2021 · External reference
The role of LPD-nanoparticles containing recombinant major surface glycoprotein of Leishmania (rgp63) in protection against leishmaniasis in murine model
10.1080/08923973.2017.1407941 · 2018 · External reference
Vaccine efficacy induced by virus-like particles containing Leishmania donovani surface glycoprotein GP63
2024 · External reference
A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis
10.1016/j.cellimm.2020.104194 · 2020 · External reference
Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection
10.1016/j.molimm.2018.12.025 · 2019 · External reference
Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice
10.1016/j.molimm.2016.12.022 · 2017 · External reference
A Tailored Approach to Leishmaniases Vaccination: Comparative Evaluation of the Efficacy and Cross-Protection Capacity of DNA vs. Peptide-Based Vaccines in a Murine Model
10.3390/ijms241512334 · 2023 · External reference
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
10.1371/journal.pntd.0005527 · 2017 · External reference
Expression of Toll-like receptors in nasal epithelium in allergic rhinitis
10.1111/apm.12408 · 2015 · External reference
Unresolved reference
External reference
Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy
10.1111/tmi.13382 · 2020 · External reference
Unresolved reference
External reference
Resistance to Leishmania major induced by tolerance to a single antigen
10.1126/science.274.5286.421 · 1996 · External reference
Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36
10.1016/s1286-4579(01)01426-5 · 2001 · External reference
Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum
10.1046/j.1432-1327.1999.00122.x · 1999 · External reference
Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
10.1084/jem.186.7.1137 · 1997 · External reference
Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
10.1038/4000 · 1998 · External reference
Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice
10.1016/j.vaccine.2006.11.060 · 2007 · External reference
Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK
10.1128/iai.72.8.4521-4527.2004 · 2004 · External reference
Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters
10.3389/fimmu.2018.00843 · 2018 · External reference
Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection
10.1016/j.vaccine.2009.08.091 · 2009 · External reference
Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response
10.1016/j.vaccine.2007.11.021 · 2008 · External reference
Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK
10.1016/s0264-410x(03)00032-x · 2003 · External reference
The antibiotic resistance-free mammalian expression plasmid vector pPAL for development of third generation vaccines
10.1016/j.plasmid.2018.12.002 · 2019 · External reference
A non-replicative antibiotic resistance-free DNA vaccine delivered by the intranasal route protects against canine leishmaniasis
10.3389/fimmu.2023.1213193 · 2023 · External reference
Functional genomics in sand fly-derived Leishmania promastigotes
10.1371/journal.pntd.0007288 · 2019 · External reference
Leishmaniosis canina y humana: Una visión de conjunto
2006 · External reference
Unresolved reference
2012 · External reference
Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis
10.1016/j.vetpar.2006.01.011 · 2006 · External reference
Canine leishmaniasis: the key points for qPCR result interpretation
10.1186/1756-3305-4-57 · 2011 · External reference
Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis
10.1016/j.vetpar.2009.05.022 · 2009 · External reference
LeishVet guidelines for the practical management of canine leishmaniosis
10.1186/1756-3305-4-86 · 2011 · External reference
A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasons
10.1371/journal.pntd.0003213 · 2014 · External reference
Guidelines for diagnosis and clinical classification of leishmaniasis in dogs
10.2460/javma.236.11.1184 · 2010 · External reference
Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates
2017 · External reference
Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine
10.1016/j.vetpar.2006.05.001 · 2006 · External reference
The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection
10.1016/j.vaccine.2009.07.069 · 2009 · External reference
Epidemiological implications of the use of various methods for the diagnosis of canine leishmaniasis in dogs with different characteristics and in differing prevalence scenarios
10.1007/s00436-011-2812-7 · 2012 · External reference
A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend® against canine leishmaniosis
10.1016/j.vaccine.2018.02.111 · 2018 · External reference
Overview of Commercial Vaccines Against Canine Visceral Leishmaniasis: Current Landscape and Future Directions
10.3390/pathogens14100970 · 2025 · External reference
World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence-Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis
2025 · External reference
IL12 p35 and p40 subunit genes administered as pPAL plasmid constructs do not improve protection of pPAL-LACK vaccine against canine leishmaniasis
10.1371/journal.pone.0212136 · 2019 · External reference
Evaluation of canine leishmaniosis vaccine CaniLeish® under field conditions in native dog populations from an endemic Mediterranean area-A randomized controlled trial
10.1016/j.actatropica.2020.105387 · 2020 · External reference
Unresolved reference
External reference
Seasonal dynamics of phlebotomine sand flies and autochthonous transmission of Leishmania infantum in high-altitude ecosystems in southern Spain
10.1016/j.actatropica.2020.105749 · 2021 · External reference
Field study of the improved rapid sand fly exposure test in areas endemic for canine leishmaniasis
10.1371/journal.pntd.0007832 · 2019 · External reference
Seasonal dynamics of canine antibody response to Phlebotomus perniciosus saliva in an endemic area of Leishmania infantum
10.1186/s13071-018-3123-y · 2018 · External reference
Serological evaluation of selected vector-borne pathogens in owned dogs from northern Spain based on a multicenter study using a commercial test
10.1186/s13071-020-04172-5 · 2020 · External reference
Latest trends in Leishmania infantum infection in dogs in Spain, Part I: mapped seroprevalence and sand fly distributions
10.1186/s13071-020-04081-7 · 2020 · External reference
Seasonal Dynamics of Phlebotomine Sand Fly Species Proven Vectors of Mediterranean Leishmaniasis Caused by Leishmania infantum
10.1371/journal.pntd.0004458 · 2016 · External reference
Characterisation of the ex vivo virulence of Leishmania infantum isolates from Phlebotomus perniciosus from an outbreak of human leishmaniosis in Madrid, Spain
10.1186/s13071-014-0499-1 · 2014 · External reference
Could wild rabbits (Oryctolagus cuniculus) be reservoirs for Leishmania infantum in the focus of Madrid, Spain?
10.1016/j.vetpar.2014.03.027 · 2014 · External reference
Phlebotomine sand fly survey in the focus of leishmaniasis in Madrid, Spain (2012-2014): seasonal dynamics, Leishmania infantum infection rates and blood meal preferences
10.1186/s13071-017-2309-z · 2017 · External reference
Performance of Leishmania PFR1 recombinant antigen in serological diagnosis of asymptomatic canine leishmaniosis by ELISA
10.1186/s12917-017-1224-z · 2017 · External reference
Serological diagnosis of canine leishmaniosis: comparison of three commercially available tests
10.1007/s00436-014-3865-1 · 2014 · External reference
Performance of commercially available serological diagnostic tests to detect Leishmania infantum infection on experimentally infected dogs
10.1016/j.vetpar.2012.09.009 · 2013 · External reference
Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity
10.1128/jcm.42.11.5249-5255.2004 · 2004 · External reference
Quantifying the contribution of hosts with different parasite concentrations to the transmission of visceral leishmaniasis in Ethiopia
10.1371/journal.pntd.0003288 · 2014 · External reference
Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN)
10.1016/s0264-410x(02)00294-3 · 2002 · External reference
Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis
10.1016/j.vaccine.2013.12.046 · 2014 · External reference
Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naive dogs exposed to three consecutive transmission seasons
10.1128/jcm.44.4.1318-1322.2006 · 2006 · External reference
A long term experimental study of canine visceral leishmaniasis
10.1016/j.ijpara.2006.11.007 · 2007 · External reference
Immunoprophylaxis pharmacotherapy against canine leishmaniosis: A systematic review and meta-analysis on the efficacy of vaccines approved in European Union
10.1016/j.vaccine.2020.08.051 · 2020 · External reference
Canine Leishmaniasis: Update on Epidemiology, Diagnosis, Treatment, and Prevention
2022 · External reference
Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population
10.1016/j.vetpar.2014.04.025 · 2014 · External reference
Ability of immunodiagnostic tests to differentiate between dogs naturally infected with Leishmania infantum and Leishmune(®)-vaccinated dogs
10.1007/s11259-015-9625-6 · 2015 · External reference
The Use of Specific Serological Biomarkers to Detect CaniLeish Vaccination in Dogs
10.3389/fvets.2019.00373 · 2019 · External reference
The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine
10.1016/j.vaccine.2005.11.061 · 2006 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Advances in intranasal vaccine delivery: A promising non-invasive route of immunization
10.1016/j.vaccine.2023.05.011 · 2023 · External reference
Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose
10.1016/j.vaccine.2011.10.092 · 2012 · External reference
DNA Vaccines: History, Molecular Mechanisms and Future Perspectives
10.1016/j.jmb.2023.168297 · 2023 · External reference
